Table 2.
Historical controls (N = 11) | Denosumab subjects (N = 4) | |
---|---|---|
Modeling‐based fluorochrome labeling at the femoral neck, n (%) | ||
Cancellous | 9 (81.8) | 4 (100.0) |
Endocortical | 9 (81.8) | 4 (100.0) |
Periosteal | 11 (100.0) | 4 (100.0) |
N = number of subjects with an evaluable biopsy for fluorochrome labeling; n = number of subjects with observed data.